Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Karo Bio AB Extends Research Collaboration with Pfizer Inc
Karo Bio AB announced the extension of its existing research collaboration with Pfizer Inc on RORgamma modulators to the end of 2014. Pfizer will continue to provide full funding for the research costs. The collaboration that started in December 2011, aims to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases. Pfizer is responsible for all research costs of the project. Karo Bio is eligible to receive over USD 200 million in milestone payments in addition to any royalty fees.
Latest Key Developments in Biotechnology
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Novation Holdings Inc Announces Acquisition Of Controlling Interest In Solar Energy Initiatives Inc
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Portola Pharmaceuticals Inc Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity Of Eliquis
- Share this
- Link this
- Digg this
Follow Reuters